Table 2.
Clinical benefit of sunitinib in the phase I/II trial in imatinib refractory gastrointestinal stromal tumor by primary and secondary tumor genotype.
| Primary mutation (n = 77) | Secondary mutation (n = 65) | n | Clinical benefit (%) |
|---|---|---|---|
| KIT mutation | 64 | 42 | |
| Exon 9 | 19 | 58 | |
| None | 13 | 62 | |
| KIT exon 13 | 1 | 100 | |
| KIT exon 17 | 2 | 0 | |
| Exon 11 | 44 | 34 | |
| None | 10 | 10 | |
| KIT exon 13/14 | 17 | 59 | |
| KIT exon 17/18 | 10 | 10 | |
| Exon 13 | KIT exon 17 | 1 | 100 |
| PDGFRA mutation | 4 | 0 | |
| Exon 12 | PDGFRA exon 18 | 1 | 0 |
| Exon 18 | 3 | 0 | |
| None | 2 | 0 | |
| KIT/PDGFRA WT | 9 | 56 | |
| None | 8 | 50 |
Clinical benefit, response or stable disease for ≥ 6 months.
PDGFRA, platelet-derived growth factor receptor α; WT, wild type.